PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA).
体外研究
PF-4693627 also inhibits mPGES-1 with IC50s of 180 and 6 nM in HWB-1483 and human fetal fibroblast, respectively.
PF-4693627 shows high activity in lipopolysaccharide (LPS) stimulated human whole blood (HWB) cell assay (IC50=109 nM).
体内研究
PF-4693627 (10 mg/kg; orally) inhibits 63% of PGE2 production relative to vehicle control in Guinea pig carrageenan stimulated air pouch model.
PF-4693627 (1.0 mg/kg; i.v.) shows good bioavailability (59%) and modest half life (t1/2=3.7 h) in Sprague-Dawley rats.
Animal Model:
Guinea pig with carrageenan stimulated air pouch inflammation model
Dosage:
10 mg/kg
Administration:
Administered orally
Result:
63% PGE2 inhibition.
Animal Model:
Sprague-Dawley rats.
Dosage:
1.0 mg/kg (Pharmacokinetic Analysis)
Administration:
Administered i.v.
Result:
Clearance (CL), volume of distribution (Vdss), t1/2, mean residence time (MRT) and bioavailability (F) is 12 mL/min/kg, 3.0 L/kg, 3.7 h, 4.42 h, 59%, respectively.
分子式
C26H29N3O3Cl2
分子量
502.43
CAS号
1312815-93-2
运输条件
Room temperature in continental US; may vary elsewhere.